Drug Profile
MK 8226
Alternative Names: MK-8226Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 16 Nov 2014 Merck terminates a phase I trial in Atopic dermatitis in USA (NCT01732510)
- 25 Feb 2013 Phase-I clinical trials in Atopic dermatitis in USA (IV)
- 31 Dec 2011 Preclinical trials in Atopic dermatitis in USA (IV)